Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-05-26
2000-09-26
Davis, Zinna Northington
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
5483345, C07D21710, C07D23354
Patent
active
061244619
ABSTRACT:
Vasoactive compounds are described for the treatment of erectile dysfunction and impotence. The compounds are reaction products of an anionic or negatively charged vasoactive or erection-inducing component and a cationic or positively charged vasoactive or erection-inducing component. These components are combined as acids and bases to form an organic salt or ionically bonded compound. The compounds have advantageous solubility characteristics and efficacy. A compound of the invention is combined with a pharmaceutical vehicle to form a composition which preferably includes an emulsifier. A local anesthetic and/or androgenic steroids may also be included. Compositions of the invention may also include more than one vasoactive organic salt compound. The composition can be advantageously formulated and administered to allow self-adjusted dosing, while minimizing or preventing overdosing.
REFERENCES:
patent: 4801587 (1989-01-01), Voss et al.
patent: 5145852 (1992-09-01), Virag
patent: 5242391 (1993-09-01), Place et al.
patent: 5447912 (1995-09-01), Gerstenberg et al.
patent: 5482039 (1996-01-01), Place
patent: 5552157 (1996-09-01), Yagi et al.
patent: 5565466 (1996-10-01), Gioco et al.
patent: 5567706 (1996-10-01), Gavras
patent: 5583144 (1996-12-01), Kral
patent: 5648350 (1997-07-01), DeLignieres et al.
patent: 5658936 (1997-08-01), Kifor et al.
Hellstrom et al. "A double-blind, placebo-controlled evaluation of the erile response to transurethral alprostadil" Urology 1996;48(6):851-6.
Padma-Nathan et al. "Treatment of men with erectile dysfunction with transurethral alprostadil" Medicated Urethral System for Erection (MUSE) Study Group N Eng J Med 1997 Jan;336(1):1-7.
Purvis et al. "Determinants of satisfactory rigidity after intracaverosal injection with prostaglandin E1 in men with erectile failure" Int J Impot Res 1996;8(1):9-16.
Hedlund et al. "Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models" Scand J. Urol Nephrol Suppl 1996;179:129-38.
Schramek et al. "Intracavernous injection of prostaglandin E.sub.1 plus procaine in the treatment of erectile dysfunction" J. Urol 1994;152:1108-1110.
Kattan, S. "Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence" Urology 1995 Jun;45(6):1032-6.
Wolfson et al. "Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction" Urology 1993;42:73-5.
Schouman et al. "Suppression of prostaglandin E-1 induced pain by dilution of the drug with lidocaine before intracavernosal injection" J. Urology 1992;148:1226, letter.
Tanaka, T. "Papaverine hydrochloride in peripheral blood and the degree of penile erection" J. Urology 1990;143:1135-7.
Cawello et al. "Pharmacokinetics of prostaglandin E1 and its main metabolites after Intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction" J. Urol 1997 Oct;158(4):1403-7.
Sundaram et al, "Long-term follow-up of patients receiving injection therapy for erectile dysfunction" Urology 1997 Jun;49(6):932-5.
Soderahl et al. "Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction" Br J. Urol 1997 Jun;79(6):952-7.
McMahon, CG "Nonsurgical treatment of cavernosal venous leakage" Urology 1997 Jan;49(1):97-100.
Hellstrom et al. "A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil" Urology 1996 Dec;48(6):851-6.
Chen et al. "The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction" J. Urol 1995 Jan;153(1):80-1.
National Institutes of Health: Impotence. Consensus Development Conference Statement. Int J. Imp Res 1993;5:181.
McMahon, CG "A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolaime, Prostaglandin E-1 and a combination of all three agents in the management of impotence" Int. J. Impot Res 1991;3:113.
Shenfeld et al. "Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study" J. Urol 1995 Sep;154(3):1017-9.
Lue et al. "Impotence [editorial]" J. Urol 1995 Jul;154(1):85.
Virag, R. "Intracavernous injection of papaverine for erectile failure" Lancet 1982;2:938.
Brindley, GS "Cavernosal alpha-blockage: a new technique for investigating and treating erectile impotence" Br J. Psychiatry 1983;143:332.
Furlow, W.L. "Prevalence of impotence in the United States" Med. Aspects Hum Sex 1985 19:13-8.
Flynn et al. "Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or with phentolamine" J. Urology 1996 Oct; 78(4):628-631.
Lea et al. "Intracavernous Alprostadil A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Erectile Dysfunction" Drugs & Aging 1996 Jan;8(1):56-74.
Vaidyanathan et al. "Myocardial infarction associatd with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia" [letter] Spinal Cord 1996 Dec;34(12):754-5.
Chiang et al. "Papaverine and Prostaglandin E.sub.1 Gel Applications for Impotence" Ann Acad Med Singapore 1995 Sep;24(5):767-9.
Kim et al. "Papaverine Topical Gel for Treatment of Erectile Dysfunction" J.Urol. Feb 1995, 153(2):361-5.
Seidmon et al. "The pH Analysis of Papaverine-Phentolamine and Prostaglandin E.sub.1 for Pharmacologic Erection" J. Urology 1989 Jun.;141:1458-9.
Godschalk et al. "Alkalization Does Not Alleviate Penile Pain Induced By Intracavernous Injection of Prostaglandin E1" J Urol 1996 Sep;156(3):999-1000.
Tostain, et al. "Traitement des troubles erectiles par les androgenes: Quand? Comment?," [Androgen Treatment of Erectile Dysfunction: When? How?] Progres en Urologie, vol. 7, pp. 314-319 (1997).
Marin, "Testosterone and Regional Fat Distribution," Obesity Research, vol. 3, Suppl., pp. 609s-611s (Nov. 4 1995).
MUSE description sheet, two pages, dated Nov. 1996.
Physician Desk Reference, misc. pp. 864-865 (1997).
Physician Desk Reference misc. p. 1523 (1997).
Scala et al., "Male Erectile Dysfunction", Feb. 12, 1998.
Govier et al., "Timing of Penile Color Flow Duplex Ultrasonography Using a Triple Drug Mixture", The Journal of Urologie, vol. 153, pp. 1472-1475 (1995).
Porst, "The Rationale for Prostaglandin E1 In Erectile Failure: A survey of Worldwide Experience", The Journal of Urolgie, vol. 155, pp. 802-815 (1996).
Porst, "The Rationale For Prostaglandin E1 in Erectile Failure: a Survey of Worldwide Experience", "The Virtual Medical Center," mediconsult.com, pp. 1-3 (date unknown).
Bechara et al., "Prostaglandin E1 Versus Mixture of Prostaglandin E1, Papaverine and Phentolamine in Nonresponders To High Papaverine Plus Phentolamine Doses", The Journal of Urologie, vol. 155, pp. 913-914 (1996).
Fallon, "Intracavernous Injection Therapy For male Erectile Dysfunction", Urologic Clinics of North America, vol. 22, No. 4, pp. 833-845 (1995).
Bennett et al., 514 Abstract of: "An Improved Vasoactive Drug Combination For A Pharmacological Erection Program (PEP)", undated.
Sikora et al., 516 Abstract of: "Subjective and Objective Success-Parameters After Dorsal Venous Ligature In Erectile Dysfunction", undated.
Chao et al., excerpt from: "Experience with Intracavernosal Tri-mixture for the Management of Neurogenic Erectile Dysfunction", Medical Center Compounding Pharmacy, Intracorporeal Injections, (two pages)(undated).
"Urethra and Penis--disorders of function", Chapter 32, pp. 521-523, (unknown author) (origin unknown).
"Treating Impotence With Hormones and Drugs", pp. 143-147, (unknown author) (origins unknown).
"Injection of the Corpora Cavernosa With Pharmacologic Agents (Papaverine, Phentolamine)", pp. 1-4 (1995).
Davis Zinna Northington
Saint Louis University, Health Services Center, Research Adminis
LandOfFree
Compounds, compositions, and methods for treating erectile dysfu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions, and methods for treating erectile dysfu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions, and methods for treating erectile dysfu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2101279